Subscribe: Apple Podcasts | Android | RSS
Monoclonals — powerful therapeutics derived from the cells of people infected with diseases — are an essential tool in our fight against the pandemic. The FDA recently granted emergency use authorization to a new monoclonal cocktail developed by Eli Lilly. One of its components, bamlanivimab, was proven in January to be massively effective among COVID patients in nursing homes (which have been a key driver of deaths). We spoke with Dr. Myron Cohen of UNC, one of the principal investigators and architects of the bamlanivimab nursing home trial, about monoclonals, the future of the fight against COVID, and his own groundbreaking work on HIV and how it made the work he does today possible.